Centre for Addiction and Mental Health
250 College Street
Toronto, Ontario M5T 1R8
(416) 535-8501 ext. 4750
Dr. Gary Remington is Director of the Medication Assessment Program (MAPS) and Deputy Director, Research & Education in the Schizophrenia Program. He is Professor of Psychiatry with the Faculty of Medicine at the University of Toronto.
Areas of Research
Dr. Remington’s research focus is in the pharmacotherapy of schizophrenia, particularly as it applies to the pharmacology and clinical profile of new antipsychotics and decision-making in antipsychotic therapy. He is currently part of a working group at the University of Toronto where the concentration has been on the role of dopamine, using in vitro (receptor binding), in vivo (PET), pre-clinical, and human clinical studies. Dr. Remington is also conducting clinical trials to study pharmacological strategies that might include clinical response, as well as assist in the management of antipsychotic-related side effects.
View Dr. Remington's publications on PubMed.